Southridge Partners II (formerly Southridge Capital Management) Enters into a $20 Million Equity Purchase Agreement with Bio-Matrix Scientific Group Inc.
RIDGEFIELD CT, April 30, 2012 – Stephen M. Hicks, Chairman and CEO of Southridge Capital, announced today that Southridge Partners II (formerly Southridge Capital Management), an institutional investor, has entered into a $20 million equity purchase agreement with Bio-Matrix Scientific Group, Inc., a biotechnology company focused on the development of regenerative medicine therapies and tools.
Bio-Matrix Scientific Group, Inc. (BMSN), a San Diego, California based research and development company, is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.
Southridge seeks investments in emerging growth areas, domestically and in international markets. Southridge has successfully participated in providing over $1.7 billion in capital to companies in the United States, Asia, Canada, the United Kingdom and Australia amongst other markets.
About Southridge Advisors
Southridge LLC is a diversified financial holding company specializing in direct investment and advisory services to small and middle market companies. Read on for more about another one of Southridge Capital’s exciting investments.